Axiron is a drug owned by Eli Lilly And Co. that contains testosterone as an active ingredient. First authorized for market use on November 23, 2010, Axiron holds a total of 7 drug patents, out of which 1 has expired.
The last patent for Axiron is set to expire on September 27, 2027. Following this date, it is likely that generic versions of Axiron will become available on the market. This release date is dependent on the patent's expiry date rather than on a Para IV filing.
Axiron is utilized as a method for transdermally delivering testosterone. It helps in increasing the testosterone blood level in a person in need thereof. This method can be used particularly in adult male subjects who need an increase in their testosterone blood level.
Axiron holds seven patents. The last patent for Axiron is due to expire on September 27, 2027, which will likely pave the way for the release of Axiron generic alternatives. Below are the details of the patents: